Pfizer Returns To Roivant As Development Partner For A Second Time
Executive Summary
Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.
You may also be interested in...
Roivant/Roche: Did Pfizer Miss Out?
Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.
Roche Makes Play For Bowel Disease Leadership With $7.1bn Roivant Deal
The Swiss pharma company has followed Merck & Co. and Sanofi by buying into the TL1A-inhibitor class, with pharma chief Teresa Graham confident RVT-3101 could be its next best-in-class blockbuster
‘It’s A Very Different Story,’ Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue
The company lowered Paxlovid and Comirnaty 2023 revenue projections by $9bn, announced plans for the commercial transition of the products, and revealed a cost-cutting plan.